These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 31721154

  • 21. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep 19; 144(38):59. PubMed ID: 12395712
    [No Abstract] [Full Text] [Related]

  • 22. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec 03; 159(11):I-14. PubMed ID: 24297207
    [No Abstract] [Full Text] [Related]

  • 23. [A case of chronic inflammatory demyelinating polyradiculoneuropathy after treatment with pegylated interferon α-2a in a patient with chronic hepatitis B virus infection].
    Naito H, Takeda I, Segawa A, Tsuge M, Maruyama H, Matsumoto M.
    Rinsho Shinkeigaku; 2016 Oct 28; 56(10):672-677. PubMed ID: 27680223
    [Abstract] [Full Text] [Related]

  • 24. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
    Iwasaki Y, Ikeda F, Yamamoto K.
    Nihon Rinsho; 2011 May 28; 69 Suppl 4():215-20. PubMed ID: 22096922
    [No Abstract] [Full Text] [Related]

  • 25. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M, Hernàndez J, Arenas MD, Carnicer F, Caramelo C, Fabrizi F.
    Kidney Blood Press Res; 2015 May 28; 40(3):258-65. PubMed ID: 25997572
    [Abstract] [Full Text] [Related]

  • 26. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N, Besheer T, Gad Y, Elbendary A, Mokbel T, Abdel-Aziz A.
    J Ocul Pharmacol Ther; 2013 Apr 28; 29(3):345-8. PubMed ID: 23113644
    [Abstract] [Full Text] [Related]

  • 27. Effective long-term alpha-interferon treatment for hypereosinophilic syndrome.
    Canonica GW, Passalacqua G, Pronzato C, Corbetta L, Bagnasco M.
    J Allergy Clin Immunol; 1995 Jul 28; 96(1):131-3. PubMed ID: 7622756
    [No Abstract] [Full Text] [Related]

  • 28. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection.
    Maughan A, Ogbuagu O.
    Expert Opin Drug Metab Toxicol; 2018 Feb 28; 14(2):219-227. PubMed ID: 29271660
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M, Piattelli M, Annese M, Maio G, Conte D, Guadagnino V, Pazienza V, Festi D, Spirito F, Andriulli A.
    J Viral Hepat; 2005 May 28; 12(3):292-9. PubMed ID: 15850470
    [Abstract] [Full Text] [Related]

  • 32. Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.
    Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM.
    Eur J Gastroenterol Hepatol; 2012 May 28; 24(5):543-50. PubMed ID: 22337287
    [Abstract] [Full Text] [Related]

  • 33. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C, Pérez-Álvarez R.
    Arch Soc Esp Oftalmol; 2011 Jun 28; 86(6):193-5. PubMed ID: 21767697
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.
    Suh DJ, Lee HC, Byun KS, Cho M, Kweon YO, Tak WY, Chon CY, Koh KC, Lee YS.
    Antivir Ther; 2013 Jun 28; 18(6):765-73. PubMed ID: 23900457
    [Abstract] [Full Text] [Related]

  • 35. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome.
    Butterfield JH, Gleich GJ.
    Ann Intern Med; 1994 Nov 01; 121(9):648-53. PubMed ID: 7944072
    [Abstract] [Full Text] [Related]

  • 36. Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.
    Mahajan S, Avasthi A, Grover S, Chawla YK.
    J Psychosom Res; 2014 Aug 01; 77(2):109-15. PubMed ID: 25077851
    [Abstract] [Full Text] [Related]

  • 37. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
    Hüsken AC, Tsianakas A, Hensen P, Nashan D, Loquai C, Beissert S, Luger TA, Sunderkötter C, Schiller M.
    J Eur Acad Dermatol Venereol; 2012 Jan 01; 26(1):71-8. PubMed ID: 22168776
    [Abstract] [Full Text] [Related]

  • 38. Excellent response to interferon therapy in a patient with hypereosinophilic syndrome and elevated serum immunoglobulin E levels.
    Acaba L, Mangual A, Vélez García E.
    Bol Asoc Med P R; 2000 Jan 01; 92(4-8):59-62. PubMed ID: 11143821
    [Abstract] [Full Text] [Related]

  • 39. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study.
    Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, Hung PH, Kao JH, Liu CJ, Lai MY, Chen JH, Chen PJ, Kao JH, Chen DS.
    Gut; 2008 Apr 01; 57(4):525-30. PubMed ID: 17881538
    [Abstract] [Full Text] [Related]

  • 40. Chronic inflammatory demyelinating polyneuropathy due to the administration of pegylated interferon α-2b: a neuropathology case report.
    Shiga K, Tanaka E, Isayama R, Mizuno T, Itoh K, Nakagawa M.
    Intern Med; 2012 Apr 01; 51(2):217-21. PubMed ID: 22246494
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.